Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Other financing activities (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Other financing activities for 4 consecutive years, with $67132.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other financing activities fell 68.81% to $67132.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $895203.0, a 12.21% decrease, with the full-year FY2023 number at $748823.0, up 201.23% from a year prior.
  • Other financing activities was $67132.0 for Q3 2025 at bioAffinity Technologies, down from $326616.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $326616.0 in Q1 2025 to a low of -$77081.0 in Q3 2022.
  • A 4-year average of $167410.0 and a median of $186445.0 in 2023 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: soared 538.02% in 2023, then tumbled 68.81% in 2025.
  • bioAffinity Technologies' Other financing activities stood at $192941.0 in 2022, then increased by 21.54% to $234510.0 in 2023, then decreased by 8.21% to $215260.0 in 2024, then tumbled by 68.81% to $67132.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Other financing activities are $67132.0 (Q3 2025), $326616.0 (Q1 2025), and $215260.0 (Q3 2024).